Since for advanced stage NSCLC patients, epidermal growth factor receptor (EGFR) mutation status may play a role in postoperative outcome, we further compared the EGFR sensitive mutation ratio in NOP high expression patients and NOP low expression patients with stage III-IV and found no statistical difference (53.8 vs. 48.3%, respectively, P = 0.649). Here, EGFR is linked to non-small cell lung carcinoma.